Table 4 Advances in the research of mRNA antibodies

Sponsor

Beijing Institute of Microbiology and Epidemiology

Wuhan Institute of Virology

University of Pennsylvania

VIB-UGent Center for Medical Biotechnology

Infectious Disease Research Institute

Tübingen

Moderna, Inc.

Fudan University

Georgia Institute of Technology and Emory University

Georgia Institute of Technology and Emory University

Dongtai People’s Hospital

Massachusetts Institute of Technology

BioNTech

niversity of North Carolina at Chapel Hill Chapel Hill

Tübingen

Moderna, Inc.

Moderna, Inc.

Dosege

0.2 and 1 mg/kg

5 × 10⁵ IU

1 and 1.4 mg/kg

5 µg

40 µg

40 µg

0.1, 0.3 and 0.6 mg/kg

2.5 mg/kg

20 and 100 µg

100 µg

0.2, 0.6 and 2 mg/kg

8 mg/kg

5 µg

1 mg/kg

40 µg

1 mg/kg

1 mg/kg

Route

I.V.

I.T.

I.V.

I.T.

I.M.

I.M.

I.V.

I.V.

I.T.

I.T.

I.V.

I.V.

I.V.

I.V.

I.V.

I.V.

I.V.

Main components of vector

DSPC, cholesterol and PEG-lipid

PEG-lipid, cholesterol, ionizable cationic lipid

DOTAP and cholesterol

Squalene, glyceryl trimyristate, DOTAP

Phosphatidylcholine, cholesterol, PEG-lipid

DSPC, cholesterol and PEG-lipid

DSPC, cholesterol, DMG-PEG2000

Phosphatidylcholine, PEGylated lipid cholesterol

cKK-E12

TransIT-mRNA Transfection kit

MC3 LNPs

Phosphatidylcholine, cholesterol, PEG-lipid

Undisclosed

Undisclosed

Indication

RBD

RBD

HIV-1 gp120

FcgRIV & M2e

ZIKV

Rabies

CHIKV

HBsAg

RSV

RSV

PD1

HER2

TAAs

CCL2 & CCL5

Botulinum toxin

O5-antigen

Psl

Diseases

SARS-CoV-2

SARS-CoV-2

HIV-1

Influenza A Virus

Zika Virus

Rabies

Chikungunya virus

Hepatitis B Virus

Respiratory syncytial virus

Respiratory syncytial virus

Oncology

Oncology

Oncology

Oncology

Toxins

STm

PA

Format

IgG

IgG

IgG

Bispecific

IgG

IgG

IgG

scFv, scFv-Fc, IgG

IgG

VHH

IgG

IgG

Bispecific

Bispecific

VNA

IgA2

IgA1

Antibodies

HB27

CB6

VRC01

RiboBiFE

ZIKV-117

S057(CR57)

mRNA-1944

G12

Palivizumab

RSV aVHH

Pembrolizumab

Trastuzumab

RiboMAbs

BisCCL2/5i

BoNT/A

Sal4

CAM003